A Study of Duvelisib and Venetoclax in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Indolent or Aggressive Non-Hodgkin Lymphoma, Who Have Not Previously Received a Bcl-2 or PI3K Inhibitor
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- John Hayslip, MD
AbbVie
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Site Reference Id/investigator# 145677
Tucson, Arizona, United States
- Site Reference Id/investigator# 147922
Chicago, Illinois, United States
- Site Reference Id/investigator# 148562
Harvey, Illinois, United States
- Site Reference Id/investigator# 148561
Goshen, Indiana, United States
- Site Reference Id/investigator# 145674
Baltimore, Maryland, United States
- Site Reference Id/investigator# 145145
Boston, Massachusetts, United States
- Site Reference Id/investigator# 148010
Detroit, Michigan, United States
- Site Reference Id/investigator# 147747
St Louis, Missouri, United States
- Site Reference Id/investigator# 145146
Lebanon, New Hampshire, United States
- Site Reference Id/investigator# 148559
Greenville, South Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jul 2016
- Primary completion
- 31 Jan 2020
- Completion
- 28 Feb 2021
- Last update posted
- 26 Jul 2016
- Registered enrollment
- 0
- Registry id
- NCT02640833
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.